Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.
Experimental Neurology. 2004-09-01; 189(1): 1-4
DOI: 10.1016/j.expneurol.2004.05.016
Read on PubMed
1. Exp Neurol. 2004 Sep;189(1):1-4.
Rise and fall of minocycline in neuroprotection: need to promote publication of
negative results.
Diguet E(1), Gross CE, Tison F, Bezard E.
Author information:
(1)CNRS UMR 5543, Université Victor Segalen Bordeaux2, Bordeaux, France.
Initial studies conducted on the neuroprotective effects of minocycline, a
second-generation tetracycline, in experimental models of neurodegeneration gave
promising results. However, more recently, minocycline has clearly been shown to
have variable and even contradictory (beneficial or detrimental) effects in
different species and models of neurological disorders, and its “neuroprotective”
mechanisms remain to be clarified. Although its anti-inflammatory properties are
likely to contribute to its neuroprotective effects observed in several animal
models, a body of recent evidence indicates that our community should proceed
with caution in the clinical use of minocycline for central nervous system
disorders.
DOI: 10.1016/j.expneurol.2004.05.016
PMID: 15296829 [Indexed for MEDLINE]